Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

, ALNY

Alnylam

$70.30

1.73 (2.52%)

06:49
10/06/16
10/06
06:49
10/06/16
06:49

Piper thinks Alnylam failure is positive for Ionis

Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,

IONS

Ionis Pharmaceuticals

$36.38

0.72 (2.02%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

GSK

GlaxoSmithKline

$43.33

-0.11 (-0.25%)

  • 07

    Oct

  • 14

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals
$36.38

0.72 (2.02%)

10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
JANY
09/28/16
INITIATION
Target $47
JANY
Buy
Ionis Pharmaceuticals initiated with a Buy at Janney Capital
Janney Capital analyst Roy Buchanan initiated Ionis Pharmaceuticals with a Buy and a $47 fair value estimate. Buchanan believes the late stage pipeline, including wholly-owned volanesorsen, and the base technology can add meaningful value to Ionis. 1H 2017 is particularly rich with 3 phase 3 readouts, with potential for another early, interim look at SMA.
ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
10/06/16
JPMS
10/06/16
DOWNGRADE
Target $51
JPMS
Neutral
Alnylam downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded Alnylam Pharmaceuticals to Neutral after the company said it will discontinue Revusiran for the treatment of Familial Amyloid Cardiomyopathy. The analyst viewed the drug as a "key asset" and cut his price target for the shares to $51 from $83. Barclays this morning also downgraded Alnylam.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $106
PIPR
Overweight
Alnylam selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views today's selloff in shares of Alnylam Pharmaceuticals after the company discontinued its revusiran program as a buying opportunity. The analyst does not believe the discontinuation has read-through to the Phase III APOLLO trial or seven other RNAi drugs that employ ESC-GalNAc technology. He lowered his price target for Alnylam shares to $106 from $118 and keeps an Overweight rating on the name. JPMorgan and Barclays this morning downgraded the shares.
10/06/16
LEER
10/06/16
DOWNGRADE
Target $40
LEER
Market Perform
Alnylam downgraded to Market Perform from Outperform at Leerink
Leerink analyst Michael Schmidt downgraded Alnylam Pharmaceuticals to Market Perform after the company discontinued development of revusiran. To reflect an increased level of uncertainty around the company's pipeline, the analyst cut his price target for the shares to $40 from $107. JPMorgan and Barclays also downgraded Alnylam this morning while Piper Jaffray recommends buying the stock on weakness.
GSK GlaxoSmithKline
$43.33

-0.11 (-0.25%)

09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Underperform
GlaxoSmithKline downgraded to Underperform from Neutral at Exane BNP Paribas
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
GlaxoSmithKline initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started GlaxoSmithKline with an Overweight rating and GBP 20 price target. The company's growth is defensive and its risks are declining, Purkiss tells investors in a research note.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:50
09/19/17
09/19
16:50
09/19/17
16:50
Technical Analysis
Technical View: Bed Bath & Beyond tumbles after earnings miss expectations »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$156.60

0.83 (0.53%)

16:48
09/19/17
09/19
16:48
09/19/17
16:48
Earnings
Adobe sees Q4 adjusted EPS of about $1.15, consensus $1.10 »

Sees Q4 revenue about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

VNO

Vornado

$73.37

-1.19 (-1.60%)

16:48
09/19/17
09/19
16:48
09/19/17
16:48
Hot Stocks
Vornado provides information regarding its investment in Toys 'R Us »

Vornado announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

16:47
09/19/17
09/19
16:47
09/19/17
16:47
Hot Stocks
Ocean Rig UDW announces 1-for-9,200 reverse stock split »

Ocean Rig UDW announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXAR

Axar Acquisition Corp

16:45
09/19/17
09/19
16:45
09/19/17
16:45
Hot Stocks
Axar Acquisition announces redemption of outstanding shares and dissolution »

Axar Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:44
09/19/17
09/19
16:44
09/19/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBU

Brookfield Business Partners

$31.08

0.08 (0.26%)

, BAM

Brookfield

$40.14

0.02 (0.05%)

16:40
09/19/17
09/19
16:40
09/19/17
16:40
Syndicate
Brookfield Business Partners announces $600M equity offering »

Brookfield Business…

BBU

Brookfield Business Partners

$31.08

0.08 (0.26%)

BAM

Brookfield

$40.14

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MXWL

Maxwell

$6.29

-0.24 (-3.68%)

16:40
09/19/17
09/19
16:40
09/19/17
16:40
Syndicate
Maxwell files to sell $50M of convertible senior notes due 2022 »

Maxwell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

16:38
09/19/17
09/19
16:38
09/19/17
16:38
Syndicate
Iovance Biotherapeutics files to sell $50M of common stock »

Jefferies and Wells…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FB

Facebook

$172.52

2.51 (1.48%)

16:37
09/19/17
09/19
16:37
09/19/17
16:37
Periodicals
Facebook public hearing will happen according to Senator Burr, Bloomberg says »

According to Bloomberg,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ELS

Equity Lifestyle

$87.87

-0.23 (-0.26%)

16:35
09/19/17
09/19
16:35
09/19/17
16:35
Hot Stocks
Equity Lifestyle provides update on Hurricane Irma impact, reaffirms guidance »

Equity LifeStyle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 30

    Jan

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:35
09/19/17
09/19
16:35
09/19/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

MXWL

Maxwell

$6.29

-0.24 (-3.68%)

16:34
09/19/17
09/19
16:34
09/19/17
16:34
Hot Stocks
Maxwell enters into Amended and Restated Agreement with Viex »

Maxwell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$48.29

0.84 (1.77%)

16:33
09/19/17
09/19
16:33
09/19/17
16:33
Hot Stocks
Mercury Systems receives $3.8M order for advanced electronic warfare application »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$37.12

0.12 (0.32%)

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
HFF Inc. announces sale of office in Raleigh-Durham, NC for $105.5M »

Holliday Fenoglio Fowler…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Options
Preliminary option volume of 13.8M today »

Preliminary option volume…

RYAM

Rayonier Advanced Materials

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
Rayonier Advanced Materials estimates impact from Hurricane Irma »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$75.95

-1.35 (-1.75%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
Earnings
Analogic sees FY18 EPS $2.70 to $2.90, two estimates consensus $2.80 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, TMUS

T-Mobile

$65.42

3.62 (5.86%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
General news
On The Fly: Top stock stories for Tuesday »

Stocks searched for a…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

TMUS

T-Mobile

$65.42

3.62 (5.86%)

S

Sprint

$8.20

0.52 (6.77%)

VZ

Verizon

$49.34

1.25 (2.60%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

DTEGY

Deutsche Telekom

$18.75

0.68 (3.76%)

BOBE

Bob Evans

$77.41

4.48 (6.14%)

POST

Post Holdings

$86.36

0.52 (0.61%)

RAD

Rite Aid

$2.40

-0.33 (-12.09%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

KSS

Kohl's

$45.38

0.49 (1.09%)

AZO

AutoZone

$535.19

-28.21 (-5.01%)

SNCR

Synchronoss

$9.82

-6.93 (-41.37%)

REV

Revlon

$17.05

1.05 (6.56%)

BBY

Best Buy

$52.76

-4.59 (-8.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 09

    Nov

  • 16

    May

FDX

FedEx

$216.00

0.92 (0.43%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Earnings
FedEx sees FY18 ex-items EPS $12.00-$12.80, consensus $13.38 »

The company is lowering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

CSTM

Constellium

$10.00

0.4 (4.17%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Hot Stocks
Constellium signs contract with Pilatus to support jet aircraft program »

Constellium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 02

    Oct

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

16:25
09/19/17
09/19
16:25
09/19/17
16:25
Conference/Events
Gemphire Therapeutics to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

SERV

ServiceMaster

$47.06

0.1 (0.21%)

16:23
09/19/17
09/19
16:23
09/19/17
16:23
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSC

Harsco

$19.90

0.4 (2.05%)

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Harsco gets orders from D.C and Sacramento, CA for safety systems »

Harsco Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

, TPGI

Now owned by PKY

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Sabra to acquire 49% equity interest in senior housing managed by Enlivant »

Sabra Health Care,…

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

TPGI

Now owned by PKY

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.